TALZENNA is the first and only PARP inhibitor approved in combination with standard of care…
PHARMA & CLINICAL TRIALS
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental…
The University of Rochester will house a new national center focused on using tissue-on-chip technology to develop…
Merck and Harpoon Therapeutics today announced that the companies have entered into a definitive agreement…
An average of 22 adolescents 14 to 18 years of age died in the U.S.…
Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical…
The world’s largest review on opioid medicines for cancer pain has found it is unclear…